{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:43:48Z","timestamp":1767894228196,"version":"3.49.0"},"reference-count":91,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Neurodegener. Dis. Manag."],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.2217\/nmt-2021-0014","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T11:21:17Z","timestamp":1630927277000},"page":"387-409","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":47,"title":["An Updated Review of teriflunomide\u2019s Use in Multiple Sclerosis"],"prefix":"10.1080","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-7356","authenticated-orcid":false,"given":"Aaron E","family":"Miller","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai New York City\rNY\r10029\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13819"},{"key":"e_1_3_4_4_1","volume-title":"Atlas of MS (3rd Edition).","author":"Multiple Sclerosis International Federation","year":"2020","unstructured":"Multiple Sclerosis International Federation . Atlas of MS (3rd Edition). (2020). https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30481-1"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2016-0029"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25463"},{"key":"e_1_3_4_8_1","unstructured":"Betaseron (interferon beta-1b) for injection [prescribing information]. Bayer HealthCare Pharmaceuticals Inc NJ USA (2019)."},{"key":"e_1_3_4_9_1","unstructured":"Extavia (interferon beta-1b) for injection [prescribing information]. Novartis Pharmaceuticals Corp NJ USA (2019)."},{"key":"e_1_3_4_10_1","unstructured":"Avonex (interferon beta-1a) injection [prescribing information]. Biogen Inc MA USA (2020)."},{"key":"e_1_3_4_11_1","unstructured":"Rebif (interferon beta-1a) [prescribing information]. EMD Serono Inc MA USA (2020)."},{"key":"e_1_3_4_12_1","unstructured":"Plegridy (peginterferon beta-1a) injection [prescribing information]. Biogen Inc MA USA (2020)."},{"key":"e_1_3_4_13_1","unstructured":"Copaxone (glatiramer acetate injection) [prescribing information]. Teva Neuroscience Inc NJ USA (2020)."},{"key":"e_1_3_4_14_1","unstructured":"Gilenya (fingolimod) capsules [prescribing information]. Novartis Pharmaceuticals Corp NJ USA (2019)."},{"key":"e_1_3_4_15_1","unstructured":"Zeposia (ozanimod) capsules [prescribing information]. Celgene Corp NJ USA (2020)."},{"key":"e_1_3_4_16_1","unstructured":"Mayzent (siponimod) tablets [prescribing information]. Novartis Pharmaceuticals Corp NJ USA (2019)."},{"key":"e_1_3_4_17_1","unstructured":"Tecfidera (dimethyl fumarate) delayed-release capsules [prescribing information]. Biogen Inc MA USA (2019)."},{"key":"e_1_3_4_18_1","unstructured":"Vumerity (diroximel fumarate) delayed-release capsules [prescribing information]. Alkermes Inc MA USA (2019)."},{"key":"e_1_3_4_19_1","unstructured":"Bafiertam (monomethyl fumarate) delayed-release capsules [prescribing information]. Banner Life Sciences LLC NC USA (2020)."},{"key":"e_1_3_4_20_1","unstructured":"Mavenclad (cladribine) tablets [prescribing information]. EMD Serono Inc MA USA (2019)."},{"key":"e_1_3_4_21_1","unstructured":"Tysabri (natalizumab) injection [prescribing information]. Biogen Inc MA USA (2020)."},{"key":"e_1_3_4_22_1","unstructured":"Lemtrada (alemtuzumab) [prescribing information]. Genzyme Corp MA USA (2020)."},{"key":"e_1_3_4_23_1","unstructured":"Ocrevus (ocrelizumab) injection [prescribing information]. Genentech Inc CA USA (2020)."},{"key":"e_1_3_4_24_1","unstructured":"Kesimpta (ofatumumab) [prescribing information]. Novartis Pharmaceuticals Corp NJ USA (2020)."},{"key":"e_1_3_4_25_1","unstructured":"Aubagio (teriflunomide) [prescribing information]. Genzyme Corp MA USA (2019)."},{"key":"e_1_3_4_26_1","unstructured":"Aubagio (teriflunomide) summary of product characteristics. Sanofi-Aventis Groupe Paris France (2018)."},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000390"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420970754"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014656"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.02.011"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.800483"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0212-x"},{"key":"e_1_3_4_33_1","volume-title":"31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.","author":"Wiendl H","year":"2015","unstructured":"Wiendl H , GrossCC, LindnerMet al. Characterizing the impact of teriflunomide on adaptive immune cell subsets, repertoire and function in patients with relapsing remitting MS: TERI-DYNAMIC. Presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.Barcelona, Spain,7\u201310 October 2015."},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519851981"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000070"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31829e6fbf"},{"key":"e_1_3_4_37_1","volume-title":"35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).","author":"Prinz C","year":"2019","unstructured":"Prinz C , MillwardJM, RotheMet al. Investigating the biodistribution of the anti-inflammatory drug teriflunomide in vivo using 19F MRI and mass spectrometry. Presented at: 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Stockholm, Sweden,11\u201313 September 2019."},{"key":"e_1_3_4_38_1","volume-title":"31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.","author":"Kaplan J","year":"2015","unstructured":"Kaplan J , CavalierS, TurpaultS. Biodistribution of teriflunomide in na\u00efve rats vs rats with experimental autoimmune encephalomyelitis. Presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.Barcelona, Spain,7\u201310 October 2015."},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.86.16_supplement.P3.027"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000203121.04509.31"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70308-9"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70191-7"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513507821"},{"key":"e_1_3_4_44_1","volume-title":"6th Congress of the European Academy of Neurology (EAN).","author":"Chitnis T","year":"2020","unstructured":"Chitnis T , BanwellB, KapposLet al. TERIKIDS study: teriflunomide efficacy and safety in paediatric patients with relapsing forms of MS. Presented at: 6th Congress of the European Academy of Neurology (EAN).Virtual, 23\u201326 May 2020)."},{"issue":"3","key":"e_1_3_4_45_1","first-page":"5","article-title":"Teriflunomide efficacy and safety in pediatric patients with relapsing forms of MS: interim analysis of open-label terikids trial extension. Abstract FC02.04","volume":"26","author":"Chitnis T","year":"2020","unstructured":"Chitnis T , BanwellB, ArnoldDLet al. Teriflunomide efficacy and safety in pediatric patients with relapsing forms of MS: interim analysis of open-label terikids trial extension. Abstract FC02.04. Mult. Scler., 26(Suppl. 3), 5\u20136 (2020).","journal-title":"Mult. Scler."},{"key":"e_1_3_4_46_1","volume-title":"70th Annual Meeting of the American Academy of Neurology.","author":"Vermersch P","year":"2018","unstructured":"Vermersch P , GoldR, Meca-LallanaJEet al. Treatment satisfaction with teriflunomide in patients switching from a prior disease-modifying therapy: results from the Phase 3 TENERE extension and Phase 4 Teri-PRO clinical trials. Presented at: 70th Annual Meeting of the American Academy of Neurology.CA, USA,21\u201327 April 2018."},{"key":"e_1_3_4_47_1","volume-title":"35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).","author":"Kappos L","year":"2019","unstructured":"Kappos L , BurcklenM, FreedmanMet al. Efficacy and safety of ponesimod compared to teriflunomide in patients with relapsing multiple sclerosis: results of the randomized, active-controlled, double-blind, parallel-group Phase 3 OPTIMUM study. Presented at: 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Stockholm, Sweden,11\u201313 September 2019."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.10.010"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.09.017"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.07.006"},{"key":"e_1_3_4_52_1","volume-title":"35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).","author":"Gobbi C","year":"2019","unstructured":"Gobbi C , AchtnichtsL, DerfussTet al. Real world data from the TACO (teriflunomide in relapsing remitting multiple sclerosis patients assessing clinical benefit and patient reported outcomes) study. Presented at: 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Stockholm, Sweden,11\u201313 September 2019."},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419835077"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102659"},{"key":"e_1_3_4_55_1","volume-title":"35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).","author":"Menascu S","year":"2019","unstructured":"Menascu S , PetrouP, KarussisDet al. Real-world safety, health, and patient-reported outcomes after teriflunomide 14 mg treatment initiation in patients with relapsing remitting multiple sclerosis: teri-REAL. Presented at: 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Stockholm, Sweden,11\u201313 September 2019."},{"key":"e_1_3_4_56_1","volume-title":"35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).","author":"Hestvik AL","year":"2019","unstructured":"Hestvik AL , FrederiksenJ, NielsenHHet al. Teri-LIFE: an observational study of quality of life in patients with relapsing remitting multiple sclerosis treated with teriflunomide in the Nordic region. Presented at: 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Stockholm, Sweden,11\u201313 September 2019."},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2015.11.006"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519843055"},{"key":"e_1_3_4_59_1","volume-title":"35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).","author":"Vukusic S","year":"2019","unstructured":"Vukusic S , HellwigK, TruffinetPet al. Pregnancy outcomes in female partners of male patients treated with teriflunomide or leflunomide (the parent compound of teriflunomide). Presented at: 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Stockholm, Sweden,11\u201313 September 2019."},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02706"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/817238"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5068-8"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.21"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152712801661220"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.10.12"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2020.01.119"},{"key":"e_1_3_4_67_1","volume-title":"Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum.","author":"Edwards KR","year":"2017","unstructured":"Edwards KR , TurnerTJ, AbleRA, MandelM. Potential antiviral properties of teriflunomide: a consideration for optimizing MS treatment sequencing. Presented at: Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum.FA, USA,23\u201325 February 2017."},{"key":"e_1_3_4_68_1","volume-title":"35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).","author":"Atwood WJ","year":"2019","unstructured":"Atwood WJ , TurnerT, ChavinJ, GuikemaB, O\u2019HaraB. Effect of teriflunomide on JCPyV infection in primary astrocytes and choroid plexus epithelial cells. Presented at: 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Stockholm, Sweden,11\u201313 September 2019."},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828c2fa1"},{"key":"e_1_3_4_70_1","unstructured":"Sanofi . Pharmacovigilance data on file (31 October 2020)."},{"key":"e_1_3_4_71_1","volume-title":"34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).","author":"Akahata Y","year":"2018","unstructured":"Akahata Y , NgouthN, OhayonJet al. Teriflunomide reduces spontaneous lymphoproliferation of peripheral blood mononuclear cells from patients with human t-lymphotropic virus (HTLV)-1-associated myelopathy\/tropical spastic paraparesis. Presented at: 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Berlin, Germany,10\u201312 October 2018."},{"key":"e_1_3_4_72_1","volume-title":"8th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) \u2013 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting.","author":"Gold J","year":"2020","unstructured":"Gold J , HoldenD, ParrattJ, YiannikasC, AhmadR, GiovannoniG. Effect of teriflunomide on Epstein-Barr virus shedding in relapsing-remitting multiple sclerosis patients: outcomes from a real-world cohort study. Presented at: 8th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) \u2013 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting.DC, USA,September 11\u201313 2020."},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101388"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09944-8"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10196-9"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09921-1"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577323"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117011"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000783"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2399"},{"key":"e_1_3_4_81_1","volume-title":"7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) \u2013 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting.","author":"Woodworth L","year":"2017","unstructured":"Woodworth L , MahanA, GarronTet al. In vitro data reveals potential novel mechanism of action of teriflunomide on CNS microglia and astrocytes. Presented at: 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) \u2013 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting.Paris, France,25\u201328 October 2017."},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519855722"},{"key":"e_1_3_4_83_1","volume-title":"71st Annual Meeting of the American Academy of Neurology (AAN).","author":"Wuerfel J","year":"2019","unstructured":"Wuerfel J , MacdonnellR, SormaniMPet al. Brain volume loss and cognition in teriflunomide-treated patients in TEMSO. Presented at: 71st Annual Meeting of the American Academy of Neurology (AAN).PA, USA,4\u201310 May 2019."},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0135"},{"key":"e_1_3_4_85_1","volume-title":"34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).","author":"Sprenger T","year":"2018","unstructured":"Sprenger T , ComiG, Lebrun-FrenayCet al. Investigating the effect of teriflunomide on diffuse brain tissue damage in the Phase 3 TEMSO Study. 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Berlin, Germany,10\u201312 October 2018."},{"key":"e_1_3_4_86_1","unstructured":"Glatopa (glatiramer acetate injection) [prescribing information]. Novartis AG NJ USA 2018."},{"key":"e_1_3_4_87_1","unstructured":"Novantrone (mitoxantrone) [prescribing information]. Hospira Inc IL USA 2021."},{"key":"e_1_3_4_88_1","unstructured":"Ponvory (ponesimod) [prescribing information]. Janssen Pharmaceuticals Inc NJ USA 2021."},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002441"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102438"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.05.014"},{"key":"e_1_3_4_92_1","volume-title":"2019 Annual Meeting of the European Academy of Neurology (EAN).","author":"Sprenger T","year":"2019","unstructured":"Sprenger T , Lebrun-FrenayC, VermerschPet al. Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the Phase 3 TOPIC study. Presented at: 2019 Annual Meeting of the European Academy of Neurology (EAN).Oslo, Norway,29 June\u20132 July 2019."},{"key":"e_1_3_4_93_1","volume-title":"71st Annual Meeting of the American Academy of Neurology (AAN).","author":"Sprenger T","year":"2019","unstructured":"Sprenger T , Lebrun-FrenayC, VermerschPet al. Investigating the effect of teriflunomide on diffuse brain atrophy independent of focal disease activity in the Phase 3 TOPIC study. Presented at: 71st Annual Meeting of the American Academy of Neurology (AAN).PA, USA,4\u201310 May 2019."}],"container-title":["Neurodegenerative Disease Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/nmt-2021-0014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:46:47Z","timestamp":1716493607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/nmt-2021-0014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.2217\/nmt-2021-0014"],"URL":"https:\/\/doi.org\/10.2217\/nmt-2021-0014","relation":{},"ISSN":["1758-2024","1758-2032"],"issn-type":[{"value":"1758-2024","type":"print"},{"value":"1758-2032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}